Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute

StopCraving_12

New Member
Joined
Feb 25, 2025
Messages
1
Reaction score
0
Location
United States
"With the recent transition to the Trump administration—whose leader has repeatedly criticized pharmaceutical companies for "getting away with murder" on pricing and specifically targeted the cost of weight loss medications—I have wondered whether the FDA might reverse course under new leadership and side with compounders offering lower-priced alternatives. The FDA's new court filing indicates that the agency is standing firmly with patent holders and the drug approval system that grants market exclusivity"

 
Taking emotion out of it. It is Eli Lilly and Novo's patents for both tirzepatide and semaglutide and compound medications were never meant to be permanent. NO, I am not shilling for Lilly, just saying. I mix and match both compound, grey and brand. It all works the same. I will say Eli Lilly expanding their Cash Pay program so vials up to 10mg are now under $499 a month is a start, and more affordable for the general public.

Of course, this was a tactic to showcase availability and the medication not being in shortage.
 
Taking emotion out of it. It is Eli Lilly and Novo's patents for both tirzepatide and semaglutide and compound medications were never meant to be permanent. NO, I am not shilling for Lilly, just saying. I mix and match both compound, grey and brand. It all works the same. I will say Eli Lilly expanding their Cash Pay program so vials up to 10mg are now under $499 a month is a start, and more affordable for the general public.

Of course, this was a tactic to showcase availability and the medication not being in shortage.
That’s right, they own the patents and charge usurious rates for the meds to US patients. That’s why I can’t understand why anyone thought they’d (companies or admin) would be sympathetic to US patients, esp given they’re champions of citizen united.
 
They are publicly traded corporations with peoples retirements and huge funds invested into them. Obviously, they will answer to their customers: The shareholders. It’s just reality. They must be compelled to legally. Sure they may preemptively lower it but it would only be as a precaution in order to prevent forced legal coercion. That, or they believe they can make more money by selling more at a lower price.
 
I think the current administration is playing "show me the money" with the pharmaceutical companies and that is why they have shown stances on both sides of the issue. If Eli wants to keep the exclusivity and for Trump to continue the Biden plan to expand Medicaid and Medicare to cover the weight loss drugs in 2026 as planned they are going to have to cough up some dough to Trump. It's a sound theory but Trump is chaos, so it's anyone's guess.
 
An article with the words "Republican administration" in the title possibly getting into partisan politics? I can't imagine what you mean.
THIS “you” is a knock-out! WHY would I use a crazy squirrel when I could be gorgeous! May I steal your idea? Not that I didn’t love the Parrot.🥰
 
THIS “you” is a knock-out! WHY would I use a crazy squirrel when I could be gorgeous! May I steal your idea? Not that I didn’t love the Parrot.🥰
Of course! Yesterday I was a leopard gecko! I fully support changing your picture based on your mood. 😁
 
Lilly expanding their cash for vials program does provide an off ramp for many that were paying for compound. It is only about $100-$200 more per month than compound if on a dose <=10mg.

Still super expensive compared to gray but for many this could be an option. With insurance my Zepbound co-pay is just over $200 (for any dose) so $500 without insurance isn't as crazy as it sounds, especially if you don't have access to, or don't want to go gray.
 
Lilly expanding their cash for vials program does provide an off ramp for many that were paying for compound. It is only about $100-$200 more per month than compound if on a dose <=10mg.

Still super expensive compared to gray but for many this could be an option. With insurance my Zepbound co-pay is just over $200 (for any dose) so $500 without insurance isn't as crazy as it sounds, especially if you don't have access to, or don't want to go gray.
I believe the majority of Americans who want to use GLP1+ drugs will be unlikely to try grey, thinking that someone terrible is likely to happen if they use grey. As a result, I'm happy that Eli Lilly has made their prices for those without insurance less outrageous.
 

Trending content

Members online

Forum statistics

Threads
2,425
Messages
43,346
Members
4,346
Latest member
Sallychris
Back
Top